Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: A review

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Is glucagon-like peptide-1 fully protected by dipeptidyl peptidase 4 inhibitor administration in patients with type 2 diabetes?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cardiovascular biomarkers in clinical studies of type 2 diabetes

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Bile acids are amphipathic water-soluble steroid-based molecules best known for their important lipid-solubilizing role in the assimilation of fat. Recently, bile acids have emerged as metabolic integrators with glucose-lowering potential. Among a variety of gluco-metabolic effects, bile acids have been demonstrated to modulate the secretion of the gut-derived incretin hormone glucagon-like peptide-1 (GLP-1), possibly via the transmembrane receptor Takeda G-protein-coupled receptor 5 and the nuclear farnesoid X receptor, in intestinal L cells. The present article critically reviews current evidence connecting established glucose-lowering drugs to bile acid-induced GLP-1 secretion, and discusses whether bile acid-induced GLP-1 secretion may constitute a new basis for understanding how metformin, inhibitors of the apical sodium-dependent bile acids transporter, and bile acid sequestrants - old, new and neglected glucose-lowering drugs - improve glucose metabolism.

OriginalsprogEngelsk
TidsskriftDiabetes, Obesity and Metabolism
Sider (fra-til)1214-1222
Antal sider8
ISSN1462-8902
DOI
StatusUdgivet - sep. 2017

ID: 51454608